A recent trial demonstrated that a non-invasive neuromodulation system, led by Sinaptica Therapeutics, reduced Alzheimer’s progression by 44%. This study, part of a Phase 2 trial, offers an innovative example of how precise neurostimulation can preserve cognitive and daily functioning in patients, paving the way for future treatment strategies.
Q&A
- What is the neuromodulation system?
- How was the clinical trial conducted?
- What are the implications for Alzheimer's treatment?